NASDAQ:LUNG

Pulmonx Competitors

$45.01

+1.94 (+4.50 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$42.49

Now: $45.01▼

$46.18

50-Day Range

$43.07

MA: $52.51▼

$61.64

52-Week Range

$37.64

Now: $45.01▼

$69.48

Volume446,585 shs

Average Volume258,716 shs

Market Capitalization$1.61 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Pulmonx (NASDAQ:LUNG) Vs. INSP, HAE, IART, NARI, TNDM, and NVRO

Should you be buying LUNG stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Pulmonx, including Inspire Medical Systems (INSP), Haemonetics (HAE), Integra LifeSciences (IART), Inari Medical (NARI), Tandem Diabetes Care (TNDM), and Nevro (NVRO).

Pulmonx vs. Inspire Medical Systems Stock

Pulmonx (NASDAQ:LUNG) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Inspire Medical Systems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Inspire Medical Systems	0	3	8	0	2.73

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Inspire Medical Systems has a consensus price target of $168.5455, suggesting a potential downside of 23.81%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Inspire Medical Systems.

Valuation & Earnings

This table compares Pulmonx and Inspire Medical Systems' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Inspire Medical Systems	$82.05 million	73.25	$-33,240,000.00	($1.40)	-158.01

Pulmonx has higher earnings, but lower revenue than Inspire Medical Systems.

Insider & Institutional Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. 6.6% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Inspire Medical Systems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Inspire Medical Systems	-61.07%	-32.23%	-26.42%

Summary

Inspire Medical Systems beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Pulmonx vs. Haemonetics Stock

Pulmonx (NASDAQ:LUNG) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Haemonetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Haemonetics	0	0	4	0	3.00

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.17%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Haemonetics.

Valuation & Earnings

This table compares Pulmonx and Haemonetics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Haemonetics	$988.48 million	6.04	$76.53 million	$3.31	35.52

Haemonetics has higher revenue and earnings than Pulmonx.

Insider & Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Haemonetics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Haemonetics	11.76%	22.85%	10.40%

Summary

Haemonetics beats Pulmonx on 8 of the 11 factors compared between the two stocks.

Pulmonx vs. Integra LifeSciences Stock

Pulmonx (NASDAQ:LUNG) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Integra LifeSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Integra LifeSciences	1	4	4	0	2.33

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Integra LifeSciences has a consensus price target of $67.8889, suggesting a potential downside of 2.90%. Given Pulmonx's stronger consensus rating and higher probable upside, research analysts clearly believe Pulmonx is more favorable than Integra LifeSciences.

Valuation & Earnings

This table compares Pulmonx and Integra LifeSciences' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Integra LifeSciences	$1.52 billion	3.89	$50.20 million	$2.74	25.52

Integra LifeSciences has higher revenue and earnings than Pulmonx.

Insider & Institutional Ownership

85.7% of Integra LifeSciences shares are owned by institutional investors. 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Integra LifeSciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Integra LifeSciences	4.10%	14.26%	5.77%

Summary

Integra LifeSciences beats Pulmonx on 7 of the 11 factors compared between the two stocks.

Pulmonx vs. Inari Medical Stock

Pulmonx (NASDAQ:LUNG) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Inari Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Inari Medical	0	1	5	0	2.83

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Inari Medical has a consensus price target of $116.1667, suggesting a potential upside of 1.95%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Inari Medical.

Valuation & Earnings

This table compares Pulmonx and Inari Medical's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Inari Medical	N/A	N/A	N/A	N/A	N/A

Inari Medical has lower revenue, but higher earnings than Pulmonx.

Insider & Institutional Ownership

17.8% of Inari Medical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Inari Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Inari Medical	N/A	N/A	N/A

Pulmonx vs. Tandem Diabetes Care Stock

Pulmonx (NASDAQ:LUNG) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Pulmonx and Tandem Diabetes Care's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Tandem Diabetes Care	-11.10%	-10.98%	-5.59%

Valuation & Earnings

This table compares Pulmonx and Tandem Diabetes Care's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Tandem Diabetes Care	$362.30 million	15.18	$-24,750,000.00	($0.22)	-399.95

Pulmonx has higher earnings, but lower revenue than Tandem Diabetes Care.

Insider & Institutional Ownership

88.6% of Tandem Diabetes Care shares are owned by institutional investors. 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Tandem Diabetes Care, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Tandem Diabetes Care	0	4	9	0	2.69

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Tandem Diabetes Care has a consensus price target of $115.9231, suggesting a potential upside of 31.75%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Pulmonx.

Summary

Tandem Diabetes Care beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Pulmonx vs. Nevro Stock

Pulmonx (NASDAQ:LUNG) and Nevro (NYSE:NVRO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Pulmonx and Nevro's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	N/A	N/A	N/A
Nevro	-24.46%	-30.25%	-14.57%

Earnings & Valuation

This table compares Pulmonx and Nevro's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$32.60 million	49.28	$-20,700,000.00	N/A	N/A
Nevro	$390.26 million	12.96	$-103,690,000.00	($3.37)	-43.36

Pulmonx has higher earnings, but lower revenue than Nevro.

Analyst Ratings

This is a summary of current recommendations and price targets for Pulmonx and Nevro, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	3	5	0	2.63
Nevro	0	3	11	0	2.79

Pulmonx currently has a consensus target price of $58.00, suggesting a potential upside of 28.86%. Nevro has a consensus target price of $181.3846, suggesting a potential upside of 24.13%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Nevro.

Summary

Pulmonx beats Nevro on 6 of the 9 factors compared between the two stocks.